Parenteral Manual

Agalsidase beta (NON-FORMULARY)

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Fabrazyme
Classification: 
Enzyme, recombinant human alpha-galactosidase A
Original Date: 
October 2018
Indications: 

Enzyme replacement therapy for Fabry disease

Reconstitution and Stability: 
  • Vials should be stored in the fridge (2 to 8 degrees C)
  • Vials should be protected from light
  • Let vials stand at room temperature for 30 min prior to reconstitution
  • Reconstitute each 5 mg vial by slowly injecting 1.1 mL of sterile water for injection down the inside wall of each vial and not directly on the lyophilized cake. This will yield a 5 mg/mL solution
  • Reconstitute each 35 mg vial by slowly injecting 7.2 mL of sterile water for injection down the inside wall of each vial and not directly on the lyophilized cake. This will yield a 5 mg/mL solution
  • Do not shake vial. Gently swirl, roll and tilt the vial to mix solution
  • Stability: Reconstituted vials must be further diluted immediately following reconstitution.
  • Stability: Further diluted solution of agalsidase beta in 0.9% NaCL can be stored in the fridge for up to 24 h.

 

Available: 5 and 35 mg vials

Compatibility: 

Compatible only with 0.9% NaCL

Administration: 

(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

SC No
IM No
IV Direct No
IV intermittent infusion

Yes DO NOT SHAKE VIAL OR BAG. Gently invert further diluted solution to mix the solution.

Usual dilution: Further dilution of agalsidase beta is based on patient weight. Refer to table below

Infusion time: initial infusion rate should be no more than 15 mg/hr. With subsequent infusions, the infusion rate may be increased by 3 - 5 mg/hr

For patients weighing less than 30 kg: max infusion rate: 15 mg/hr

For patients weighing greater than or equal to 30 kg: max infusion rate is 1.5 hrs
IV continuous infusion No

 

Dosage: 

(For neonatal dosages, refer to Neonatal IV Drug Manual.)

Pediatric:

  • 1 mg/kg once every 2 weeks IV
  • Dosage adjustments can be made on an individual basis based on achievement and maintenance of therapeutic goals
  • Patients in clinical studies have received doses up to 3 mg/kg every 2 weeks IV
Potential hazards of parenteral administration: 
  • Infusion related reactions: headache, dizziness, hypotension, hypertension, nausea, fatigue and increased body temperature
  • Rare infusion related reaction symptoms: chest discomfort, dyspnea, pruritis

 

 

Notes: 
  • Infusion related reactions can be managed by slowing the infusion rate or stopping and resuming at a slower infusion rate, treatment with medications such as antihistamines, antipyretics etc.
  • Please call the physician if a patient experiences any symptoms of an infusion related reaction.
  • Agalsidase should be administered through a 0.2 micron filter
  • Agitation of the reconstituted solution or diluted bag may increase the chance for precipitation
  • Further dilution of agalsidase beta is weight dependent
    • Patient weight (kg) Minimum total volume of solution to be infused (mL)
      Less than or equal to 35 kg 50 mL
      35.1 - 70 kg 100 mL
      70.1 - 100 kg 250 mL
      Greater than 100 kg 500 mL

       

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.